ethyl 2-(3-naphthylcarbonyl-2,4-dioxo-5,5-diphenylimidazolidinyl) acetate | 472967-19-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: ethyl 2-(3-naphthylcarbonyl-2,4-dioxo-5,5-diphenylimidazolidinyl) acetate
• 英文别名: Ethyl 2-(3-naphthylcarbonyl-2,4-dioxo-5,5-diphenylimidazolidinyl)acetate；ethyl 2-[3-(naphthalene-1-carbonyl)-2,4-dioxo-5,5-diphenylimidazolidin-1-yl]acetate
• CAS: 472967-19-4
• 化学式: C₃₀H₂₄N₂O₅
• 分子量: 492.531
• InChiKey: BFUWWAURAZVLAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  37
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  84
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-Naphthylcarbonyl-5,5-diphenylimidazolidine-2,4-dione 、 溴乙酸乙酯 在 potassium carbonate 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 生成 ethyl 2-(3-naphthylcarbonyl-2,4-dioxo-5,5-diphenylimidazolidinyl) acetate
  参考文献：
  名称：

  EP1384715

  摘要：

  公开号：

文献信息

• Novel imidazolidinedione derivatives and use thereof as drugs
  申请人：——

  公开号：US20040110811A1

  公开（公告）日：2004-06-10

  The present invention is to provide an imidazolidinedione derivative and oxazolidinedione derivative represented by the following general Formula (I) having the chymase and/or tryptase inhibition activity 1 [wherein R 1 and R 2 are the same or different, and denote a lower alkyl group or a phenyl group, or R 1 and R 2 are taken together to form a ring, R 3 denotes an optionally substituted naphthyl group or heterocyclic group, A denotes oxygen or NR 4 (R 4 is hydrogen or optionally substituted lower alkyl group), or NB 2 R 5 (R 5 is aryl group, and B 2 is carbonyl group or sulfonyl group), and B 1 denotes a carbonyl group or a sulfonyl group], or a pharmaceutically acceptable salt thereof.

  本发明提供了一种由以下通式（I）表示的咪唑烷二酮衍生物和噁唑烷二酮衍生物，具有胰蛋白酶和/或胰蛋白酶抑制活性1[其中R1和R2相同或不同，表示较低的烷基或苯基，或R1和R2一起形成环，R3表示可选取代的萘基或杂环基，A表示氧或NR4（R4为氢或可选取代的较低烷基），或NB2R5（R5为芳基，B2为羰基或磺酰基），B1表示羰基或磺酰基]，或其药学上可接受的盐。
• Imidazolidinedione derivatives and use thereof as drugs
  申请人：Sakai Yusuke

  公开号：US06919365B2

  公开（公告）日：2005-07-19

  The present invention is to provide an imidazolidinedione derivative and oxazolidinedione derivative represented by the following general Formula (I) having the chymase and/or tryptase inhibition activity [wherein R 1 and R 2 are the same or different, and denote a lower alkyl group or a phenyl group, or R 1 and R 2 are taken together to form a ring, R 3 denotes an optionally substituted naphthyl group or heterocyclic group, A denotes oxygen or NR 4 (R 4 is hydrogen or optionally substituted lower alkyl group), or NB 2 R 5 (R 5 is aryl group, and B 2 is carbonyl group or sulfonyl group), and B 1 denotes a carbonyl group or a sulfonyl group], or a pharmaceutically acceptable salt thereof.

  本发明提供了一种具有chymase和/或tryptase抑制活性的咪唑啉二酮衍生物和噁唑啉二酮衍生物，其由以下一般式（I）表示[其中R1和R2相同或不同，表示较低的烷基或苯基，或R1和R2结合形成环，R3表示可选择的取代萘基或杂环基，A表示氧或NR4（R4为氢或可选择的取代较低的烷基），或NB2R5（R5为芳基，B2为羰基或磺酰基），B1表示羰基或磺酰基]，或其药学上可接受的盐。
• NOVEL IMIDAZOLIDINEDIONE DERIVATIVES AND USE THEREOF AS DRUGS
  申请人：Senju Pharmaceutical Co., Ltd.

  公开号：EP1384715A1

  公开（公告）日：2004-01-28

  The present invention is to provide an imidazolidinedione derivative and oxazolidinedione derivative represented by the following general Formula (I) having the chymase and/or tryptase inhibition activity [wherein R1 and R2 are the same or different, and denote a lower alkyl group or a phenyl group, or R1 and R2 are taken together to form a ring, R3 denotes an optionally substituted naphthyl group or heterocyclic group, A denotes oxygen or NR4 (R4 is hydrogen or optionally substituted lower alkyl group), or NB2R5 (R5 is aryl group, and B2 is carbonyl group or sulfonyl group), and B1 denotes a carbonyl group or a sulfonyl group], or a pharmaceutically acceptable salt thereof.

  本发明旨在提供具有糜蛋白酶和/或胰蛋白酶抑制活性的下通式（I）代表的咪唑烷二酮衍生物和噁唑烷二酮衍生物 [其中 R1 和 R2 相同或不同，表示低级烷基或苯基，或 R1 和 R2 合在一起形成环，R3 表示任选取代的萘基或杂环基，A 表示氧或 NR4（R4 为氢或任选取代的低级烷基），或 NB2R5（R5 为芳基，B2 为羰基或磺酰基），B1 表示羰基或磺酰基]，或其药学上可接受的盐。
• US6919365B2
  申请人：——

  公开号：US6919365B2

  公开（公告）日：2005-07-19
• EP1384715
  申请人：——

  公开号：——

  公开（公告）日：——